AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23212718 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel
Number of subjects: 400
Study 23212718 — intervention group
Group type: COMPARATOR
Intervention: Immediate release aspirin
Number of subjects: 400
Study 23213069 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 1 mg/kg
Number of subjects: 0
Study 23213069 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 4 mg/kg
Number of subjects: 0
Study 23213069 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg
Number of subjects: 0
Study 23213069 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 23213092 — intervention group
Group type: EXPERIMENTAL
Intervention: (124)I-girentuximab PET/CT
Number of subjects: 195
Study 23213092 — intervention group
Group type: COMPARATOR
Intervention: CECT
Number of subjects: 195
Study 23213094 — intervention group
Group type: EXPERIMENTAL
Intervention: Foretinib 240 mg once per day on days 1 through 5 every 14 days (intermittent arm)
Number of subjects: 74
Study 23213094 — intervention group
Group type: EXPERIMENTAL
Intervention: Foretinib 80 mg daily (daily dosing arm)
Number of subjects: 74
Study 23213094 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of germline MET mutation
Number of subjects: 74
Study 23213094 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events associated with foretinib
Number of subjects: 74
Study 23214115 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 0
Study 23214115 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 23215555 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal microarray analysis
Number of subjects: 4406
Study 23215555 — intervention group
Group type: COMPARATOR
Intervention: Karyotyping
Number of subjects: 4406
Study 23215909 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal prepregnancy body mass index (BMI)
Number of subjects: 718
Study 23215909 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI and high gestational weight gain (GWG)
Number of subjects: 718
Study 23216571 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg) and Clopidogrel (600 mg) administered prior to PPCI
Number of subjects: 48
Study 23216716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU in the morning and afternoon for 6 weeks)
Number of subjects: 19
Study 23216716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23216781 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting beads delivering irinotecan (DEBIRI)
Number of subjects: 3
Study 23216798 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine beclomethasone/formoterol
Number of subjects: 1017
Study 23216798 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol
Number of subjects: 1017
Study 23216798 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol
Number of subjects: 1017
Study 23216870 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO; a slow subcutaneous infusion via portable pump)
Number of subjects: 371
Study 23216870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chelation
Number of subjects: 371
Study 23216870 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (DFO and oral chelation)
Number of subjects: 371
Study 23216870 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence to chelation
Number of subjects: 371
Study 23216870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin iron levels
Number of subjects: 371
Study 23216870 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about treatment
Number of subjects: 371
Study 23216959 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made functional insoles
Number of subjects: 119
Study 23216959 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated insoles
Number of subjects: 119
Study 23217037 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) tablets (20mg artemether and 120mg lumefantrine)
Number of subjects: 43
Study 23217037 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects observed in patients receiving AL
Number of subjects: 43
Study 23217273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lenalidomide (5 to 10 mg/day)
Number of subjects: 15
Study 23217964 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5213 (0.05-30 mg)
Number of subjects: 7
Study 23217964 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5213 (1-14 mg/d)
Number of subjects: 7
Study 23217964 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5213
Number of subjects: 7
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-glucose
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA-105665
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: Imepitoin
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: NAX 801-2
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonabersat
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: Valnoctamide
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sec-propylbutylacetamide (SPD)
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-765
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: YK3089
Number of subjects: 100
Study 23219031 — intervention group
Group type: COMPARATOR
Intervention: Retigabine (ezogabine)
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: NAX 810-2
Number of subjects: 100
Study 23219031 — intervention group
Group type: EXPERIMENTAL
Intervention: SPD
Number of subjects: 100
Study 23221961 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPHAISTOS orthosis
Number of subjects: 11
Study 23222254 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (education, reminders, local opinion leaders, implementation teams)
Number of subjects: 1320
Study 23222363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/mL
Number of subjects: 40
Study 23222363 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study 23222688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet hydrochloride
Number of subjects: 0
Study 23222738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology panel agreement on ISHLT grades
Number of subjects: 937
Study 23222738 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade assignment by pathologists
Number of subjects: 937
Study 23222738 — intervention group
Group type: EXPERIMENTAL
Intervention: 2004 revision of ISHLT grading scheme
Number of subjects: 937
Study 23222738 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB grade ≥2R
Number of subjects: 937
Study 23222881 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PGDS in severe obstructive sleep apnoea (n = 23)
Number of subjects: 64
Study 23222881 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure treatment for 2 days in severe obstructive sleep apnoea (n = 12)
Number of subjects: 64
Study 23222881 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning urinary L-PGDS concentrations
Number of subjects: 64
Study 23223100 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype NIRS monitor
Number of subjects: 70
Study 23223100 — intervention group
Group type: COMPARATOR
Intervention: Personal computer-based COx
Number of subjects: 70
Study 23223434 — intervention group
Group type: EXPERIMENTAL
Intervention: 53 single-nucleotide polymorphisms (SNPs) identified as significant predictors of inhibitor status after adjustment for potential confounders.
Number of subjects: 833
Study 23223434 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 of the 53 SNPs were significant predictors among the discordant pairs.
Number of subjects: 833
Study 23224059 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 234
Study 23224059 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia during pregnancy
Number of subjects: 234
Study 23225085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment TARC levels
Number of subjects: 0
Study 23225085 — intervention group
Group type: EXPERIMENTAL
Intervention: TARC levels
Number of subjects: 0
Study 23225523 — intervention group
Group type: EXPERIMENTAL
Intervention: Preendoscopy treatment
Number of subjects: 2660
Study 23225523 — intervention group
Group type: EXPERIMENTAL
Intervention: Postendoscopic pharmacological therapy
Number of subjects: 2660
Study 23225523 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic procedures during endoscopy
Number of subjects: 2660
Study 23225523 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resource consumption
Number of subjects: 2660
Study 23225523 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from admission to endoscopy
Number of subjects: 2660
Study 23225902 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Ankara (MVA)
Number of subjects: 151
Study 23226015 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated exacerbations (n = 164)
Number of subjects: 23
Study 23226015 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation length (determined for 17 patients)
Number of subjects: 23
Study 23226015 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment delay
Number of subjects: 23
Study 23226015 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to resolution of exacerbation after treatment initiation
Number of subjects: 23
Study 23226204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg PO twice daily) plus carboplatin (AUC=6) and paclitaxel (225 mg/m(2)) administered IV on day 1 for up to 6 cycles, followed by sorafenib monotherapy until disease progression
Number of subjects: 25
Study 23227182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic analysis using a combined direct injection and LC-MS/MS assay (AbsolutIDQ p180 kit)
Number of subjects: 142
Study 23227182 — intervention group
Group type: COMPARATOR
Intervention: Neonates with Hypoxic ischaemic encephalopathy
Number of subjects: 142
Study 23227182 — intervention group
Group type: COMPARATOR
Intervention: Both study groups (HIE and asphyxiated infants)
Number of subjects: 142
Study 23227182 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model using 5 metabolites
Number of subjects: 142
Study 23228035 — intervention group
Group type: EXPERIMENTAL
Intervention: R115777 administered twice per day for 21 days of a 28-day cycle.
Number of subjects: 14
Study 23228045 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EDOCH14-R (two-weekly dose-adjusted EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab)
Number of subjects: 20
Study 23228045 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EDOCH14-R
Number of subjects: 20
Study 23228045 — intervention group
Group type: COMPARATOR
Intervention: DA-EPOCH-R (3-weekly DA-EPOCH-R)
Number of subjects: 20
Study 23228045 — intervention group
Group type: COMPARATOR
Intervention: DA-EPOCH-R
Number of subjects: 20
Study 23228190 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg QD) combined with cisplatin (60 mg/m(2) d1 q 3w) and capecitabine (1250 mg/m(2) bid d1-14 q 21)
Number of subjects: 35
Study 23228190 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg QD) combined with cisplatin (50 mg/m(2) d1 q 2w) and 5-fluoruracil (2 g/m(2) d1, q 1w)
Number of subjects: 35
Study 23228190 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (300 mg QD)
Number of subjects: 35
Study 23228190 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (700 mg QD)
Number of subjects: 35
Study 23228190 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg QD)
Number of subjects: 35
Study 23228190 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (not specified)
Number of subjects: 35
Study 23228299 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23228446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, and Sunitinib (GCS)
Number of subjects: 45
Study 23228990 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2DG) at 63 mg/kg/day combined with docetaxel at 30 mg/m(2) for 3 of every 4 weeks.
Number of subjects: 34
Study 23228990 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2DG) at 63 mg/kg/day
Number of subjects: 34
Study 23229679 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoma patients (15 patients)
Number of subjects: 87
Study 23229679 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (15 patients)
Number of subjects: 87
Study 23229679 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoma patients
Number of subjects: 87
Study 23229679 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoma type B2 patients
Number of subjects: 87
Study 23229692 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with optic disc hemorrhages (DH)
Number of subjects: 2607
Study 23229692 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with 2 or more optic disc hemorrhages (DH)
Number of subjects: 2607
Study 23229692 — intervention group
Group type: COMPARATOR
Intervention: Eyes initially randomized to treatment
Number of subjects: 2607
Study 23229692 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with recurrent optic disc hemorrhages (DH)
Number of subjects: 2607
Study 23229696 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish CLS; Sensimed AG (24-hour IOP monitoring)
Number of subjects: 40
Study 23229886 — intervention group
Group type: EXPERIMENTAL
Intervention: Algenpantucel-L immunotherapy in addition to gemcitabine and 5-fluorouracil-based chemoradiotherapy
Number of subjects: 70
Study 23230059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 3.0 mg/kg for infants 0-8 months
Number of subjects: 87
Study 23230059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 3.5 mg/kg for subjects 9-11 months
Number of subjects: 87
Study 23230059 — intervention group
Group type: COMPARATOR
Intervention: FDA-approved unit dose of 30 mg for subjects 12-23 months
Number of subjects: 87
Study 23230059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment
Number of subjects: 87
Study 23230457 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive systolic blood pressure (BP) lowering for acute hypertension in ICH patients
Number of subjects: 0
Study 23230457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine
Number of subjects: 0
Study 23230457 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter study for hyperacute BP lowering (the SAMURAI-ICH study)
Number of subjects: 0
Study 23231599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1
Study 23231599 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study 23232038 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25-100 μg once daily
Number of subjects: 0
Study 23232038 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 100 μg
Number of subjects: 0
Study 23232038 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) (all doses)
Number of subjects: 0
Study 23232250 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté
Number of subjects: 1282
Study 23232587 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC BMI percentile (96th percentile)
Number of subjects: 369
Study 23232587 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC BMI percentile (94th percentile)
Number of subjects: 369
Study 23232587 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC BMI percentile (95th percentile)
Number of subjects: 369
Study 23233047 — intervention group
Group type: EXPERIMENTAL
Intervention: High MSI2 expression
Number of subjects: 454
Study 23233047 — intervention group
Group type: EXPERIMENTAL
Intervention: NUMB expression
Number of subjects: 454
Study 23233387 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site HV measurement using ABC/2 method
Number of subjects: 56
Study 23233387 — intervention group
Group type: COMPARATOR
Intervention: Central HV measurement using ABC/2 method
Number of subjects: 56
Study 23233387 — intervention group
Group type: COMPARATOR
Intervention: MIPAV HV measurement
Number of subjects: 56
Study 23233538 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23233571 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage therapy (specific regimens not detailed)
Number of subjects: 0
Study 23233571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution genomic analyses of matched pairs of diagnostic and relapse bone marrow samples
Number of subjects: 0
Study 23233718 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Yttrium-ibritumomab-tiuxetan ((90)YIT)
Number of subjects: 59
Study 23234268 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCap Hip Resurfacing System implant (Biomet Inc., Warsaw, USA)
Number of subjects: 240
Study 23234514 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded cord blood with mesenchymal stromal cells
Number of subjects: 31
Study 23234514 — intervention group
Group type: COMPARATOR
Intervention: Unmanipulated cord blood
Number of subjects: 31
Study 23235268 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated 7-item Quality of Life Scale (QLS)
Number of subjects: 1460
Study 23236082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (not specified)
Number of subjects: 701
Study 23236082 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity
Number of subjects: 701
Study 23236082 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a boyfriend
Number of subjects: 701
Study 23236375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis patients (n=15)
Number of subjects: 42
Study 23236375 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS patients (n=13)
Number of subjects: 42
Study 23237128 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies during hospitalization and after discharge
Number of subjects: 10568
Study 23237128 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combinations of antithrombotic therapies during hospitalization
Number of subjects: 10568
Study 23237128 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in antithrombotic treatments during 24-month follow-up
Number of subjects: 10568
Study 23237982 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg daily
Number of subjects: 482
Study 23238591 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-11 (rhIL-11, Neumega®)
Number of subjects: 9
Study 23238660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 400
Study 23238660 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated Hemoglobin (HbA1c)
Number of subjects: 400
Study 23238660 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Algorithm
Number of subjects: 400
Study 23238879 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus treatment
Number of subjects: 44
Study 23238879 — intervention group
Group type: COMPARATOR
Intervention: K-RAS mutations
Number of subjects: 44
Study 23239552 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hepatic lobectomy
Number of subjects: 12
Study 23240851 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan delivered via convection-enhanced delivery (CED) at a total dose of 0.403 mg in 6.04 ml over 100 hours for the first patient, and 0.284 mg in 5.30 ml over 100 hours for the second patient.
Number of subjects: 2
Study 23241251 — intervention group
Group type: EXPERIMENTAL
Intervention: Guggulsterone (oral administration)
Number of subjects: 15
Study 23241455 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs supplementation (1.14 g DHA and 1.56 g EPA from six fish oil capsules per day for twelve weeks)
Number of subjects: 20
Study 23241455 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs supplementation
Number of subjects: 20
Study 23242239 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback interventions to improve prescribing safety data (two active arms)
Number of subjects: 262
Study 23242239 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 262
Study 23242479 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated activity relative to others' age, 5-point Likert Scale
Number of subjects: 3410
Study 23242479 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative activity
Number of subjects: 3410
Study 23242479 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-predictor associations with age
Number of subjects: 3410
Study 23242596 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2 for 7 days followed by escalating doses of lenalidomide daily for 21 days starting on day 8 of each cycle every 6 weeks
Number of subjects: 42
Study 23242601 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with MTX/IFO/DEP followed by high-dose chemotherapy with carmustine, thiotepa, etoposide, and autologous stem cell transplantation (HD-ASCT)
Number of subjects: 30
Study 23242601 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with carmustine, thiotepa, etoposide, and autologous stem cell transplantation (HD-ASCT)
Number of subjects: 30
Study 23242601 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with MTX/IFO/DEP
Number of subjects: 30
Study 23242601 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with AraC/TT/DEP
Number of subjects: 30
Study 23242601 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with HD-ASCT
Number of subjects: 30
Study 23243055 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily temozolomide (50 mg/m2) continuously until progression
Number of subjects: 47
Study 23243282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg per day on days 1 to 21 of each 28-day cycle
Number of subjects: 38